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Summary The DOM project is a non-randomized population-based breast cancer screening programme in Utrecht which started in 1974-75.
The 17-year effect has been evaluated by a case-control study of breast cancer deaths dunng the period 1975-92 in women living in the city
of Utrecht, bom between 1911 and 1925. whose breast cancers were diagnosed after the initiation of the DOM project. Controls (three for
each case) were defined as women having the same year of birth as the case, living in the city of Utrecht at the time the case died. and having
had the opportunity of screening in the DOM project. Screening in the period 1975-92 indicated a breast cancer mortality reduction of 46°,
(odds ratio of 0.54. 950o confidence interval 0.37-0.79). The strongest protective effect was found at a screening interval of 2 years or less
(mortality reduction of 62%, odds ratio of 0.38), and for the highest number of screens (mortality reduction of 68%, odds ratio of 0.32 for more
than four screens). Exclusion of breast cancer deaths that occurred within 1 year of diagnosis, to allow for 'lead-time' bias, gave an odds ratio
of 0.61. Early diagnosis of breast cancer by screening reduces breast cancer mortality in the long term. Bias due to the study design may
slightty overestimate the protective effect. A screening programme with a 2-yearly, or smaller, interval between successive screens will
improve the protection of screening.
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The purpose ofthe present paper is to evaluate long-term benefits of
the breast cancer screening in the DOM project in The Netherlands.
bv means of a nested case-control studv. Exaluation Awas made of
t-o particular forms of bias to which attention has recent1s been
drawn (Hosek et al. 1996; Weiss and Lazoxich. 1996).
SUBJECTS AND METHODS
The DOM [Diacnostisch Onderzoek (investigation) Mamma-
carcinoom] project started in December 1974 in the city of
Utrecht. Initiallv. the screening A-as limited to A-omen aged 50-64
at intake (birth cohort 191 1-25). and thev A-ere screened bv
mammography. Of 20 555 eligible A-omen. 14 697 (72%7c) attended
for screening. The intervals between successive screening exami-
nations (screens) w-ere of different length. namelv 1. 1'/,. 2 and 4
x-ears. At the first examination. both mediolateral and craniocaudal
projections A-ere obtained: in subsequent examinations. mammog-
raphx was restricted to the mediolateral projection. A w-oman who
did not participate in the first screeningv was not invited for the
second screening and so on.
Fixe examinations had been completed by 1984. A breast cancer
registry was set up and cooperation w-ith general practitioners.
local authorities and the Central Bureau for Statistics (CBS)
ensured the followi-up of the invited A-omen. More detailed infor-
mation about the screening design has been described prexiously
(Collette et al. 1984. 1992: de Waard et al. 1984). From 1985
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onwards. the DOM project was graduallv integrated in the nation-
viide breast cancer screeninc programme in The Netherlands. This
programme invites woiomen aged 50-69. at 2-vear intervals and
independently ofpreceding participation. to be screened.
In the present study. cases u-ere defined as breast cancer deaths
in the period 1975-92 in woiomen living in the city of Utrecht w-ho
v-ere born betvieen 1911 and 1925 and whose breast cancers were
diagnosed betuveen 1975 and 1992. Information about tumour size.
axillarv status and mode ofdetection of the breast cancers at diag-
nosis w-ere extracted from the DONI project breast cancer registry.
Causes of death wiere provided by gYeneral practitioners or hospi-
tals and checked agrainst the breast cancer regristrv. Controls ere
defined as women lixing in the cityv of Utrecht at the time the case
died. and havinr the same year of birth. Aae matchingr >-as done
because response rate to the screening and breast cancer mortalitx
are age dependent. For each case. three controls were selected at
random from the screening invitation file. i.e. from among all
women in the 1911-25 cohort viho were resident in Utrecht in
1974.
For all cases and controls. the screening historv was taken for
the time up to and including the date of diarnosis of the case. To
evaluate the bias of 'misclassification of exposure' )Hosek et al.
1996) due to inclusion of the diagnostic screening of screen-
detected cases that artificiallx restricts the chances of controls
haxving undergone screening. the analy-sis wvas also done excluding
these screens from the screening historx. A second form of bias.
'lead-time' bias (Weiss and Lazovich. 1996). was ealuated by
excluding breast cancer deaths wvith a short follovi-up period after
diacnosis (i.e. deaths ofpatients wvho viere less likely to hax-e been
screened). because their inclusion wiould gixe the impression of a
disproportionately large number of deaths from breast cancer in
unscreened wvomen. Maximum likelihood estimation of the odds
ratio (OR) associated with breast cancer screeningr was obtained
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Table 1 Number of matched case-control pairs. odds ratios and 95%e
confidence intervals by period of death from breast cancer (exposure defined
as at least one screening examination before or at diagnosis of the case)
Period of Case- Odds ratio Years of Rerence
death control (95% follow-up
pairs confidence
interval)
1975-81 46 0.30 (0.13-0.70) 6 Collette et al. (1984)
1975-83 59 0.35(0.17-0.71) 8 Waardetal(1986)
1975-87 116 0.52 (0.32-0.83) 12 Collette et al (1992)
1975-92 177 0.54 (0.37-0.79) 17 Current study
Tabe 2 Number of cases and controls, odds ratios, 95%: confidence
intervals, and percentage of cases and controls screened before or at
diagnosis of the case by 5-year birth cohorts (exposure defined as at least
one screening examination before or at diagnosis of the case)
Birth cohort Cases Controls Odds ratio
(% screened) (% screened) (95% confience
interval)
1911-15 63 (43) 189 (60) 0.40 (0.21-0.75)
1916-20 60 (52) 180 (66) 0.57 (0.31-1.04)
1921-25 54 (59) 162 (65) 0-71 (0.34-1.48)
1911-25 (total) 177 (51) 531 (64) 0.54 (0.37-0.79)
bv means of a conditional logistic regression analvsis for matched
sets (Breslow and Dav. 1980). This measure of effect can be
considered as an estimate of the relatixe risk. The anaixses u-ere
performed w-ith the statistical packace EGRET (Egret. 1990).
RESULTS
Betu-een 1975 and 1992. a total of 846 breast cancer cases u-ere
diacnosed in Utrecht. and for 177 of them it had been the cause of
death. Of these 177 breast cancer cases. 13%/, (n = 23) w-ere
detected by screening. 12%/ (n = 21 ) uere detected in the interval
betmeen two successive screens and 75%7c (n = 133) were not
screen detected (62 were among nexer-attenders). All 177 tumours
of the cases uwho had died x-ere invasixe at diagnosis. Most
tumours were < 20 mm: 61%. 62% and 36%7L respectivelxr in the
three detection groups.
Of the deceased breast cancer cases. 51%7 had at least one
screening examination. compared u-ith 64%/c of the control women
[OR 0.54. 95%7c confidence interval 0.37-0.79 (Tables 1 and 2)].
This indicates a 46% reduction in breast cancer mortality reduc-
tion among participants of the screening project. ORs from
previous analses of the DOM project (Collette et al. 1984. 1992:
de Uaard et al. 1986) are also presented in Table 1.
The results ofscreening on breast cancer mortalitx in the period
1975-92 stratified bx birth cohort are presented in Table 2. The
strongest protective effect wvas found in the eldest birth cohort
11911-15). and this decreased in the tu-o vounger birth cohorts.
However. the confidence intervals of the ORs are broad and these
differences are not statisticallI significant.
In Table 3. ORs are shou-n for different intervals betu-een the
last screenina examination and diagnosis of the case. the number
of screens. and participation in all offered screens before or at
diacnosis of the case. W'omen w-ho never participated (87 cases
Table 3 Number of cases and controls. odds ratios and 95O" confidence
intervals, by interval between the last screen and diagnosis of the case: by
number of screens: and by level of participation
Cases Controls Odds ratio
(95% confidence
interval)
Interval between last screen and diagnosis of the case
No screens 87 193
< 1 year 29 147
1-2 years 12 63
2-3 years 8 24
3-4 years 8 22
>4years 33 82
Number of screens before or at diagnosis of the case
0 87 193
1 27 85
2-4 49 177
5-8 14 76
1.00
0.38 (0.22-0.63)
0.38 (0.18-0.77)
0.69 (0.28-1.68)
0.85 (0.32-2.22)
0.91 (0.53-1.57)
1.00
0.67 (0.40-1.13)
0.55 (0.35-0.85)
0.32 (0.16-0.64)
Participation in all offered screensa before or at diagnosis of the case
No screens 87 193 1.00
Non-compliancet 47 129 0.73 (0.46-1.16)
Full compliancer 43 209 0.42 (0.27-0.65)
aThe number of offered screens before or at diagnosis of the case depends
on the date of diagnosis. tWomen who were screened at least once but who
did not take up all screens offered before or at diagnosis of the case.
Women who took all offered screens before or at diagnosis of the case.
and 193 controls) represented the reference group. The strongest
protectixe effect was found for the interval of 2 years or less
betuA-een the last screen and diagnosis of the case (OR 0.38. 95%'-
confidence interval 0.18-0.77). The protection of screeninee
decreased u-ith increasincg interxal periods since the last screen.
Writh reaard to the number of screens. the ORs decreased with
increasincg number of screens before diagnosis ofthe case. The OR
for women who participated in all offered screens was lower than
the OR for women without full compliance. In the present
case-control study. all screening xisits up to. and includina. the
diaenosis were counted as a positix e x-isit. For the screen-detected
cases (n = 23). the screening, examination. from which the diag-
nosis was made. was included as part of the screening, histor-. To
evaluate the possible bias due to including this examination. an
analy sis of the same data (177 matched case-control pairs) was
performed. excluding the diaonostic screening, examination.
This gave an OR of 0.38 (95%e confidence interval 0.26-0.56).
suggesting a higher protectix e effect of screening.
To evaluate lead-time-bias'. Table 4 show-s the influence of
excluding cases with successively longer follow-up times betmeen
diagnosis and dying. If this period is less than 1 year. the effect of
screening seems to be overestimated.
DISCUSSION
This case-control approach indicates a 46%e reduction in breast
cancer mortalitv after 17 years of follow--up for participants ofthe
screening programme. The strongest protective effect of screenine
is found in the oldest birth cohort. women of 60-64 years at the
start of the project. A higher lexel of protection in older women
has been described earlier in the DOM project (Collette et al.
1984. 1985. 1992) and in other studies (Tabar et al. 1995). Cancers
detected at screening wxould be expected to be of lower malignant
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Table 4 Number of matched case-control pairs. odds ratios and 95%o
confidence intervals for different lengths of time between diagnosis and
death of the case (exposure defined as at least one screening examination
before or at diagnosis of the case)
Minimal period in years between Case-control Odds ratio
diagnosis and death of the case pairs (95% confidee
interval)
0 (all cases) 177 0.54 (0.37-0.79)
1 151 0.61 (0.40-0.92)
2 126 0.64 (0.41-0.99)
3 100 0.62 (0.37-1.01)
4 79 0.56 (0.32-0.97)
5 58 0.61 (0.32-1.16)
potential than cancers that were not screen detected. In the present
studv. 61'7c of all screen-detected breast cancers were small
(< 20 mm). apercentage that is in reasonable accord with results of
the Dutch national screening programme and the Finnish study
(Hakama et al. 1995: Koning et al. 1995a). Because the present
study concerns breast cancer deaths. it is not surprising that a high
percentage (74%-) of the screen-detected tumours were axillarv
positive at diagnosis. For both cases and controls. participation in
the DONI project was low. However. some controls. of course.
responded to the screening after the pseudo-diagnosis: resulting in
higher true attendance rates of 68%-. 74%c and 78%/c. respectively.
for the three 5-year birth cohorts show in Table 2. Selection bias
due to a 'healthv screenee effect' cannot be excluded in this
case-control study. because both the number of screenings before
diagnosis ofthe case and compliance show protective effect (Table
3). Two other forms of bias in a case-control desien may also be
relevant. 'Misclassification of exposure' bias due to includine the
screening examination. from which the diaenosis was made. in the
screenin2 history of the screen-detected cases (Hosek et al. 1996)
appears to be present in the current study. Its effect is reflected in
an OR of 0.54 (with inclusion of the diagnostic screening: 95C%
confidence interval 0.37-0.79) and 0.38 (without screening: 95%7s
confidence interval 0.26-0.56). The unbiased OR may be expected
to lie between the two estimates. because systematic exclusion of
the screening examination can cause bias in the opposite direction
to that of its inclusion (Hosek et al. 1996). The other form of bias.
lead-time bias'. seems also to be present in this study. Too short a
follow-up time of incident cases leads to an artificially large
number ofdeaths from breast cancer in unscreened cases (in w-hich
lead time is absent). resultina in an overestimation of the protec-
tive effect (Weiss and Lazovich. 1996 . The present study indicates
a reduction of breast cancer mortalitv of 46%- because of
screenino. Exclusion of cases with a folloW-up time of less than 1
-ear reduces this figure to 39%c. which is in reasonable agreement
with new results from the Swedish trials: a 34%l- mortality- reduc-
tion for women aaed 50-74 y-ears (Tab.r et al. 1995) and an
expected reduction of between 24% and 32%c for women aaed
50-69 y-ears at trial entry (Koning et al. 1995b).
The estimates of the protective effect of the screening on breast
cancer mortalityv in the long term have decreased from a 70%
reduction after 6 years' follow-up. to a 48%- reduction after 12
vears' follow-up. and finally to a 46%7c reduction (95%c confidence
interval 21-631 after 17 vears follow-up (Table 1). This decrease
max be due to the followinc: first. the screeninr progammme could
have had a positive influence on the whole population. includinc
women who were never screened. by promoting awareness of
breast cancer and so increasing self-examination and readiness to
seek early medical help. Another explanation for the observed
decrease in the screening effect could be an improved therapy or a
change in aggressiveness of the disease in time. A sliaht improve-
ment ofthe prognosis ofbreast cancer during 1970-74 to 1980-84
in The Netherlands has been reported (Nab. 1995). Furthermore.
lead-time' bias could have had a larger influence in the shorter
follow-up periods of the previously published results of the DOM
project. leading to greater overestimation ofthe protective effect in
the earlier periods. Finally. it might be that in the short term the
screening partly postpones breast cancer death and partly prevents
it (Collette et al. 1984. 1985). However. after 12 and 17 years of
follow-up. the protective effect has stabilized. suggaesting a real
reduction ofbreast cancer mortality in the long term.
At the moment. the nationwide breast cancer screeninc
programme in The Netherlands invites wuomen at 2-year inten-als
(Koning et al. 1995a). whereas in the United Kingdom women are
invited everv 3 years (Patnick et al. 1995: Asburv et al. 1996). On
the basis of the results of the present study (Table 3). a 2-yearly
screening programme seems preferable to a 3-yearly proaramme.
However. these results should be interpreted with caution because
of the small number of cases and controls with an interval of 2-3
years between last screen and diaognosis ofthe case.
In the present study. protective effects of screenincy were found
in shorter screening intervals. after more screens. in older u-omen.
and in women who are willing to participate. It was not possible to
evaluate a possible interaction betmeen these factors. because of
small numbers and their inter-correlation. It is not likely that the
protective effect of screening! in the oldest 5-year birth cohort is
fully attributable to attendance at more screening examinations.
because this birth cohort saw the lowest percentage of cases and
controls who were screened two or more times.
In conclusion. early diagnosis of breast cancer by screenin2
reduces breast cancer mortality- in the longyer term. Tw-o forms of
bias due to the case-control study design seem to influence the
protective effect in different directions: the overall bias probably
results in a small overestimation of the overall protective effect.
The choice ofa 2-yearly interval in the nationwide Dutch screening
programme is supported by the results ofthe present study.
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